WO1995032731A3 - Immunogenic pharmaceuticals - Google Patents
Immunogenic pharmaceuticals Download PDFInfo
- Publication number
- WO1995032731A3 WO1995032731A3 PCT/GB1995/001274 GB9501274W WO9532731A3 WO 1995032731 A3 WO1995032731 A3 WO 1995032731A3 GB 9501274 W GB9501274 W GB 9501274W WO 9532731 A3 WO9532731 A3 WO 9532731A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- pharmaceuticals
- mutation
- immunogenic
- mutant protein
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000008300 Mutant Proteins Human genes 0.000 abstract 2
- 108010021466 Mutant Proteins Proteins 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8500539A JPH10504702A (en) | 1994-06-01 | 1995-06-01 | Immunogen preparation |
EP95921028A EP0762891A1 (en) | 1994-06-01 | 1995-06-01 | Immunogenic pharmaceuticals |
AU26237/95A AU2623795A (en) | 1994-06-01 | 1995-06-01 | Immunogenic pharmaceuticals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9410922A GB9410922D0 (en) | 1994-06-01 | 1994-06-01 | Vaccines |
GB9410922.0 | 1994-06-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995032731A2 WO1995032731A2 (en) | 1995-12-07 |
WO1995032731A3 true WO1995032731A3 (en) | 1995-12-21 |
Family
ID=10755982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/001274 WO1995032731A2 (en) | 1994-06-01 | 1995-06-01 | Immunogenic pharmaceuticals |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0762891A1 (en) |
JP (1) | JPH10504702A (en) |
AU (1) | AU2623795A (en) |
GB (1) | GB9410922D0 (en) |
WO (1) | WO1995032731A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012992A2 (en) * | 1995-10-02 | 1997-04-10 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore |
JP2001522241A (en) * | 1997-04-10 | 2001-11-13 | ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ | Diagnostic methods and reagents |
NO315238B1 (en) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptides derived from reading frame shift mutations in the TBF <beta> II or BAX gene, and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids, and virus vector-encompassing such nucleic acid |
NO314086B1 (en) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for |
ITMI20030434A1 (en) | 2003-03-07 | 2004-09-08 | Istituto Oncologico Romagnolo Coope Rativa Sociale | METHOD FOR THE DETECTION OF COLON-RECTUM TUMORS. |
JP2009532664A (en) * | 2006-02-27 | 2009-09-10 | アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ | Identification and use of novopeptides for the treatment of cancer |
US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
EP3075389A1 (en) * | 2015-03-31 | 2016-10-05 | Technische Universität München | T cell receptors and peptides derived by mutations for the treatment of cancer |
CA3065325A1 (en) | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
GB201710812D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
WO2019055618A1 (en) | 2017-09-15 | 2019-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
WO2020022901A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
EP3827263A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
WO2020022903A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER |
EP3827265A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
US20210162032A1 (en) | 2018-07-26 | 2021-06-03 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687737A (en) * | 1982-11-12 | 1987-08-18 | Massachusetts Institute Of Technology | Mammalian suppressor genes |
EP0565794A1 (en) * | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induction of CTL responses |
WO1994010323A1 (en) * | 1992-11-04 | 1994-05-11 | Imperial Cancer Research Technology Limited | Virus with modified binding moiety specific for the target cells |
-
1994
- 1994-06-01 GB GB9410922A patent/GB9410922D0/en active Pending
-
1995
- 1995-06-01 WO PCT/GB1995/001274 patent/WO1995032731A2/en not_active Application Discontinuation
- 1995-06-01 AU AU26237/95A patent/AU2623795A/en not_active Abandoned
- 1995-06-01 JP JP8500539A patent/JPH10504702A/en active Pending
- 1995-06-01 EP EP95921028A patent/EP0762891A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687737A (en) * | 1982-11-12 | 1987-08-18 | Massachusetts Institute Of Technology | Mammalian suppressor genes |
EP0565794A1 (en) * | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induction of CTL responses |
WO1994010323A1 (en) * | 1992-11-04 | 1994-05-11 | Imperial Cancer Research Technology Limited | Virus with modified binding moiety specific for the target cells |
Non-Patent Citations (4)
Title |
---|
AKIRA HORII ET AL.: "The APC gene , responsible for familial adenomatous polyposis , is mutated in human gastric cancer", CANCER RESEARCH, vol. 52, pages 3231 - 3233 * |
HARRIS C.C. ET AL.: "Clinical implications of the p53 tumor-suppressor gene", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 329, no. 18 * |
ROY N: "Generation of influenza-specific cytotoxic T-lymphocytes by retroviral gene transfer.", DISS ABSTR INT [B];54(3):1242 1993 * |
YASUO MIYOSHI ET AL.: "Somatic mutations of the APC gene in colrectal tumors : mutation cluster region in the APC gene", HUMAN MOLECULAR GENETICS, vol. 1, no. 4, pages 229 - 233 * |
Also Published As
Publication number | Publication date |
---|---|
JPH10504702A (en) | 1998-05-12 |
GB9410922D0 (en) | 1994-07-20 |
AU2623795A (en) | 1995-12-21 |
WO1995032731A2 (en) | 1995-12-07 |
EP0762891A1 (en) | 1997-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995032731A3 (en) | Immunogenic pharmaceuticals | |
GR3022124T3 (en) | A yeast cell of the genus schwanniomyces | |
WO1994026906A3 (en) | Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase | |
DE69529219D1 (en) | Helicobacter proteine und impstoffe | |
CA2240334A1 (en) | Thermostable dna polymerase from thermoanaerobacter thermohydrosulfuricus and mutant enzymes thereof with exonuclease activity removed | |
AU657487B2 (en) | Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations | |
DE69534875D1 (en) | CALCIUM-FREE SUBTILISIN MUTANT | |
WO1996022308A3 (en) | Appetite suppression factor and related methods | |
EP1688500A3 (en) | Overexpression of phytase genes in yeast systems | |
NZ335628A (en) | Improved expression vectors comprising a nucleic acid construct with tac and gal bacterial promoters | |
CA2124214A1 (en) | Materials and methods for biosynthesis of serine and serine-related products | |
WO1998021341A3 (en) | Method for the recombinant production of 1,3-propanediol | |
AU4178800A (en) | Hydantoinase variants with improved properties and their use for the production of amino acids | |
CA2252493A1 (en) | .beta.-galactoside - .alpha. 2,6-sialyltransferase gene | |
AU8258591A (en) | Human mk gene and protein sequence | |
WO1996034964A3 (en) | Stable variant hk2 polypeptide | |
DE69014046D1 (en) | Branching enzyme and its use. | |
AU7001994A (en) | Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof | |
EP0331356A3 (en) | Expression of hiv binding proteins | |
HU9801384D0 (en) | Clostridium perfringeus vaccine | |
HUP0203221A2 (en) | Genes encoding enzymes for lignin biosynthesis and uses thereof | |
EP0736602A3 (en) | Siaalpha 2,3Ga1beta 1, 4G1cNAc alpha 2,8-sialyltransferase | |
AU3950799A (en) | Genetically engineered yeast and mutants thereof for the efficient fermentation of lignocellulose hydrolysates | |
WO2001079489A3 (en) | 39228, a human alcohol dehydrogenase and uses therefor | |
ATE103979T1 (en) | HUMAN LYMPHOTOXIN. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995921028 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 750236 Date of ref document: 19970129 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1995921028 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995921028 Country of ref document: EP |